Furthermore, CD8+ T cells with decreased or loss of CD226 expression exhibit characteristics of dysfunction, and such cells are present in tumors and correlate with resistance to cancer immunotherapy (Braun et al., 2020; Weulersse et al., 2020). Here, CD226 is linked to cancer.